COMMUNIQUÉS West-GlobeNewswire

Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131

15/03/2018 - 13:00

MADISON, Wis., March 15, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment [...]

Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

15/03/2018 - 13:00

SEL-212 Severe Gout Program on Track; Additional Phase 2 Data for Higher Dose Cohorts to be Presented on April 9 th or 10 th , 2018 at PANLAR Congress Phase 1 Clinical Trial of SEL-403 for Mesothelioma Initiated Company [...]

New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2018

15/03/2018 - 13:00

Presentations will feature data on 1) the company’s Antigen Seeding Technology (AST) platform, and 2) MT-5111, an Engineered Toxin Body with a novel MOA against HER2 positive cancers AUSTIN, Texas, March 15, 2018 (GLOBE [...]

Extendicare Announces March 2018 Dividend of C$0.04 per Share

15/03/2018 - 13:00

MARKHAM, Ontario, March 15, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]

THRC’s CEO Calvin H. Knowlton, PhD Interviewed on NPR’s It’s Your Health

15/03/2018 - 13:00

MOORESTOWN, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (“TRHC”) (NASDAQ: TRHC ), Chairman and CEO Calvin H. Knowlton, PhD, recently conducted an interviewed with NPR’s Lisa Davis, host of It’ [...]

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome

15/03/2018 - 13:00

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, [...]

La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

15/03/2018 - 13:00

SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC ) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients [...]

HempAmericana Issues New Letter to Shareholders

15/03/2018 - 13:00

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) CEO issues the following letter to Shareholders: Dear Valued Shareholder, Today is 30th day that we have [...]

Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting

15/03/2018 - 12:30

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT ), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and [...]

Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference

15/03/2018 - 12:30

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 28 th Annual Oppenheimer [...]

Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells

15/03/2018 - 12:30

PHILADELPHIA and OXFORD, U.K., March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, today reported three partial responses (two confirmed and one [...]

TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting

15/03/2018 - 12:30

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced that preclinical data for TG-1601, the Company’s novel BET inhibitor, has been selected for presentation at the [...]

Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update

15/03/2018 - 12:30

- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing patients in MAGE-A4 “ [...]

Mustang Bio Announces Key Leadership Appointments

15/03/2018 - 12:30

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a Fortress Biotech (NASDAQ: FBIO ) Company focused on the development of novel immunotherapies based on proprietary chimeric [...]

FIT Biotech Oy: FIT Biotech's Review of Operations and Financial Statement 2017 published

15/03/2018 - 11:32

FIT Biotech Oy Company announcement, March 15, 2018 at 12:30 EET FIT Biotech's Review of Operations and Financial Statement 2017 published FIT Biotech's Review of Operations and Financial Statement for the year 2017 [...]

Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting

15/03/2018 - 11:30

Data from Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Durability Data in Advanced Metastatic Melanoma BERKELEY, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation ( [...]

Vical Reports Fourth Quarter 2017 Financial and Operational Results

15/03/2018 - 11:30

SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) today reported financial results for the three months ended December 31, 2017. Net loss for the fourth quarter of 2017 was $3.7 million, [...]

BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema

15/03/2018 - 11:00

RESEARCH TRIANGLE PARK, N.C., March 15, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage [...]

Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017

15/03/2018 - 11:00

NeoCart ® Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensing Agreement with MEDINET Co. Ltd. Provides Important Source of [...]